Lactococcus lactis SD-5584 and Improved Metabolic Control in Type 1 Diabetes

• A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.

  • 2023-10-02
  • RCT
  • Diabetologia 67(1)
  • • Chantal Mathieu
    • Alice Wiedeman
    • Karen Cerosaletti
    • S Alice Long
    • Elisavet Serti
    • Laura Cooney
    • Joan Vermeiren
    • Silvia Caluwaerts
    • Karolien Van Huynegem
    • Lothar Steidler
    • Sven Blomme
    • Pieter Rottiers
    • Gerald T Nepom
    • Kevan C Herold

  • PubMed: 37782353
  • DOI: 10.1007/s00125-023-06014-2

  2 Insights on

  • Improved Metabolic Control in Type 1 Diabetes

  • High evidence

  "In AG019 monotherapy-treated adults, metabolic variables were stabilised up to 6 months (C-peptide, insulin use) or 12 months (HbA1c) post treatment initiation."

  Effect

  Beneficial

  Effect size

  Small